ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. It also develops Valnivudine, an orally available small molecule compound for the prevention of post-herpetic neuralgia, as well as for the treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. has a collaboration with the Li Ka Shing Institute of Virology. The company was founded in 2013 and is headquartered in Edison, New Jersey.